Although several agents showed some clinical activity in patients with recurrent thymoma, there is no standard treatment option. Here, we report a late relapse thymoma and pure red cell aplasia case, responsive to everolimus with over 5 years of clinical benefit following multiple lines of treatment. Everolimus controlled the rapidly progressive disease in our patient without significant toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000001504 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Profiles and Survival Outcomes of Patients With Relapsed Ovarian Cancer: A Single-Center Study.
Cureus
November 2024
Medical Oncology, Madras Medical College, Chennai, IND.
Background Ovarian cancer is the third most prevalent form of cancer among women in India. The majority of patients are diagnosed at an advanced stage. Many women with late-stage ovarian cancer experience a recurrence and need subsequent treatment, even after initial therapy.
View Article and Find Full Text PDFOsteoid osteoma and osteoblastoma of the cervical spine in the pediatric population: analysis of the literature and experience with four operated cases.
Childs Nerv Syst
December 2024
Departement of Pediatric Neurosurgery, Hôpital Femme Mère Enfant, Lyon, France.
Background And Aim: Osteoid osteoma (Oo) and osteoblastoma (Ob) are rare primary bone tumors with a higher prevalence in the second decade of life. Treatment can be conservative, but in cases of spinal location, resective surgery is of great importance but may be challenging.
Material And Methods: We report four pediatric cases of Oo and Ob managed in our unit, with different locations at the level of the cervical spine.
Safety and Efficacy of Brachytherapy in Inoperable Endometrial Cancer.
J Pers Med
December 2024
Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstrasse 27, 91054 Erlangen, Germany.
: Radiotherapy represents the only treatment option for patients with inoperable endometrial cancer (EC). The aim of our study was to evaluate the efficacy and safety of brachytherapy (BT) in this selected patient population. : Between 1990 and 2019, 18 patients with inoperable EC in stage FIGO I-IV were treated with intracavitary brachytherapy using the "Heyman Packing technique".
View Article and Find Full Text PDFPelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) - study protocol paper for a phase III multicentre, open-label randomised controlled trial.
BMJ Open
December 2024
Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Introduction: Prostate cancer (PCa) is the most common cancer in men. Recurrence may occur in up to half of patients initially treated with curative intent for high-risk localised/locally advanced PCa. Pelvic nodal recurrence is common in this setting, but no clear standard of care exists for these patients, with potential therapeutic approaches including stereotactic body radiotherapy (SBRT) to the involved node(s) alone, extended nodal irradiation (ENI) to treat sites of potential micrometastatic spread in addition to involved node(s) and androgen deprivation therapy with or without additional systemic anticancer therapies.
View Article and Find Full Text PDFGPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target.
Exp Cell Res
December 2024
Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Department of Cellular and Molecular Biology, Faculty of Sciences and Advanced Technology in Biology, University of Science and Culture, Tehran, Iran. Electronic address:
Article Synopsis
- Hepatocellular carcinoma (HCC) is a significant global health concern, characterized by late diagnosis and high recurrence rates, necessitating early detection through specific biomarkers.
- Glypican-3 (GPC-3) is identified as a promising biomarker for HCC, being overexpressed in various tumors, which opens up opportunities for targeted therapies to enhance treatment outcomes.
- Recent advancements in GPC-3-targeted therapies, such as bi-specific antibodies and CAR T cell therapies, underscore its potential as both a diagnostic and therapeutic tool in the fight against HCC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!